1Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterrotomy colaplications and their management: an attempt at consensus. Gastrointest Endosc, 1991,37: 383～ 393.
2Suzuki H, Kobayashi H, Tannaka Y, et al. Structure and function analysis of urinarytrypsin inhibitor(UT 1 ) :identification of binding domains and signaling property of UTI by analysis of truncated proteins. Biochem Biophys Acta, 2001,1547: 26～ 36.
5Schofl R, Haefner M. Diagnostic cholangiopancreatography[J]. Endoscopy ,2003,35(2) : 145-155.
6Vandervoort J, Soetikno RM, Tham TC, et al. Risk factors for complications after performance of ERCP[J]. Gastrointest Endosc ,2002,56(5) :652-656.
7Christoforidis E, Goulimaris I, Kanellos I, et al. Post-ERCP pancreatitis and hyperamylasemia:petient-related and operative risk factors[ J]. Endoscopy, 2002,34 (4) : 286-292.
8Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after hiliary sphincterotomy in patients with sphincter of Oddi dysfunction[J]. Gastroenterology, 1998, 115 ( 6 ) :1518-1524.
9Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin adminitration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial [ J ].Gastrointest Endosc, 2002,56 (4):488-495.
10Raty S, Sand J, Pulkkinen M, et al. Post-ERCP pancreatitis: reduction by routine antibiotics[J]. J Gastrointest Surg,2001,5(4) : 339-345.
